Cadrenal Advances CAD-1005 Into FDA-Guided Phase 3 Trial

Cadrenal Therapeutics, Inc. ( (CVKD) ) has issued an update.

On April 30, 2026, Cadrenal Therapeutics announced it had completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration and received detailed guidance on the design of a pivotal Phase 3 trial for CAD-1005 in heparin-induced thrombocytopenia. The FDA input covered protocol design, patient population, dosing, background therapy, safety database and a primary endpoint focused on new or worsening thrombotic events.

Based on this feedback, the company plans to move directly into a randomized, blinded, placebo-controlled Phase 3 trial, enrolling about 120 patients across up to 50 centers worldwide and testing CAD-1005 on top of standard-of-care anticoagulants. The study, which follows Phase 2 data showing more than a 25% absolute reduction in thrombotic events when CAD-1005 was added to standard therapy, is intended to support a potential U.S. marketing application in 2029 and could establish the first new HIT therapy in over two decades if successful.

The most recent analyst rating on (CVKD) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Cadrenal Therapeutics, Inc. stock, see the CVKD Stock Forecast page.

Spark’s Take on CVKD Stock

According to Spark, TipRanks’ AI Analyst, CVKD is a Neutral.

The score is primarily held down by weak financial performance (no revenue, widening losses, and accelerating cash burn with declining equity) and bearish technical trends (price below all key moving averages with negative MACD). Corporate events provide some offset via near-term funding and positive preclinical updates, but dilution risk tempers the benefit; valuation signals provide limited support given the lack of meaningful earnings/dividend metrics.

To see Spark’s full report on CVKD stock, click here.

More about Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing novel therapies for life-threatening immune and thrombotic conditions. Its lead candidate, CAD-1005, is a first-in-class 12-lipoxygenase inhibitor for heparin-induced thrombocytopenia, while its broader pipeline includes tecarfarin for chronic anticoagulation and frunexian for acute hospital settings.

CAD-1005 has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration and orphan drug status from the European Medicines Agency. The company is also working on second-generation 12-LOX oral therapeutics for chronic indications, reinforcing its strategic focus on high-risk cardiovascular and hematologic disorders.

Average Trading Volume: 49,862

Technical Sentiment Signal: Sell

Current Market Cap: $14.01M

Learn more about CVKD stock on TipRanks’ Stock Analysis page.